AbbVie帕金森病口服药获FDA批准
STAT+: AbbVie wins FDA nod for Parkinson’s pill
AbbVie的帕金森病口服药物获得美国食品药品监督管理局(FDA)批准。原文未提及具体药名、适应症细分或临床试验数据细节,仅确认监管机构动作。
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
This newsletter was composed from a pediatric emergency department. Hot tip, all: Don’t jump off 6-foot playground equipment. You will scare your mother, and wind up in a cast.
The need-to-know this morning
- Kodiak Sciences said Zenkuda, its experimental vision-sparing treatment for a common cause of age-related blindness, achieved statistical equivalence to Eylea, a standard therapy, in a Phase 3 clinical trial.
- Merck said it paid $400 million upfront to China’s SciBrunch Therapeutics, for global license rights to a preclinical cancer drug that targets tumors with KRAS G12D mutations. The deal is valued at $2.13 billion if all future milestones are achieved.
Novo turns GLP-1 drugs into consumer products
Novo Nordisk is increasingly marketing its GLP-1 drugs less as treatments for a chronic disease and more as consumer products for people who simply want to lose weight, STAT’s Elaine Chen writes. It’s a shift that comes as insurance coverage for these obesity medicines remains limited.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT Pharma 医药频道 · statnews.com